VIII. 6 Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

Pain-relieving NSAIDs block the very enzyme that also protects the gut lining – so they often strain the small intestine and its barrier without any warning signs.

NSAIDs – Silent Disruptors of the Gut Barrier

Non-steroidal anti-inflammatory drugs are common, effective medicines for pain and inflammation [531].

People have been using willow bark to relieve fever and pain for at least 3,500 years. The Edwin Smith Papyrus, an Egyptian surgical text from around 1600 BC, records its use. Hippocrates recommended a brew of willow leaves for pain in childbirth. Medieval herbalists prescribed it for joint swelling. For most of this history, nobody knew why it worked. In 1828, Johann Andreas Buchner, a German pharmacist, isolated the active compound and named it salicin. By the 1870s, salicylic acid had become a widely used medicine – effective, but harsh on the stomach. In 1897, Felix Hoffmann, a chemist at Bayer in Elberfeld, synthesised a more tolerable form: acetylsalicylic acid, marketed from 1899 as Aspirin. It would become, by most measures, the most widely consumed drug in human history. The reason aspirin relieves pain is that it inhibits cyclo-oxygenase enzymes, which produce inflammatory prostaglandins. The reason it also injures the gut is exactly the same: those same enzymes produce the protective prostaglandins that maintain the intestinal mucosal barrier. One molecule. One mechanism. Two opposite consequences in the same organ. That tension is not unique to aspirin – it runs through the entire NSAID drug class, and it shapes every clinical decision about their use.

NSAIDs' effects on the gut microbiota entered the research agenda through an unexpected clinical connection: the observation that NSAID-associated small intestinal injury – a complication distinct from the better-known gastric ulceration – was modifiable by microbiota manipulation. A 2015 review by Syer and colleagues in the Journal of Gastroenterology summarised evidence that germ-free^[G] rodents did not develop the small intestinal damage seen in conventional animals given NSAIDs, providing direct evidence that the microbiota is required for NSAID enteropathy to occur. [619] The mechanism involves bile acid recycling and bacterial metabolism. NSAIDs enter the enterohepatic circulation, are conjugated in the liver, excreted into bile, and delivered to the small intestine where gut bacteria deconjugate them – regenerating the active compound that then injures the intestinal mucosa. Disrupting the microbiota with antibiotics before NSAID administration reduces enteropathic injury in animal models. [620] The human microbiota effects of chronic NSAID use include reductions in protective SCFA-producing taxa and modest shifts toward gram-negative organisms in some studies. The effect size is smaller than for antibiotics, but the clinical relevance is amplified by the scale of NSAID use: they are among the most widely used medications globally, and chronic use for pain management or cardiovascular prophylaxis exposes large populations to sustained low-level microbiota perturbation. [111] The protective strategy involves the same principle as other medication-associated microbiota disruptions: dietary fiber intake helps maintain SCFA-producing populations, and co-administration of agents that support mucosal integrity – including specific probiotics studied in NSAID enteropathy contexts – may reduce both the gastrointestinal complication rate and the associated microbiota dysregulation.

Ibuprofen, aspirin, and naproxen help many people function day to day, which is why they are used so widely. The trade-off is that the gastrointestinal tract–especially the small intestine–can be sensitive to their effects, sometimes without obvious early warning signs.

NSAIDs reduce prostaglandin production by inhibiting cyclooxygenase enzymes. Prostaglandins support mucus secretion, mucosal blood flow, and epithelial repair. When this protection is reduced, the intestinal lining can become more vulnerable, and studies in humans show that intestinal permeability can increase after NSAID exposure. In practical terms, this may allow greater immune exposure to bacterial products and dietary components, particularly in susceptible individuals.

The injury is not limited to the stomach. Modern evaluation methods, including capsule endoscopy, have shown erosions and ulcer-like lesions in the small intestine among NSAID users, and these changes are often clinically quiet. A person may feel little more than mild discomfort–or nothing at all–while microscopic damage and local inflammation develop.

Mechanistically, NSAID-related injury is not explained by prostaglandins alone. Topical, COX-independent effects also contribute, including changes in epithelial energy balance and interactions within the intestinal chemical environment. These processes can amplify mucosal stress and make recovery slower when exposure is frequent or prolonged.

The microbiota may shift during NSAID use through both direct and indirect pathways. Alterations in mucus, barrier function, and local immune signaling can change the habitat in which microbes compete and ferment nutrients. In studies of medication effects on the microbiota, concurrent drugs–particularly acid-suppressing agents–can further modify these patterns, which helps explain why results vary between individuals.

Clinically, long-term or high-dose NSAID use is associated with complications such as occult bleeding and small-bowel injury, and in patients with inflammatory bowel disease there is ongoing debate about whether certain NSAIDs increase the likelihood of flares. The safest summary is that risk appears context-dependent, influenced by drug type, dose, duration, and the patient’s underlying intestinal vulnerability.

NSAIDs remain valuable medicines. A balanced approach recognizes their benefit while acknowledging that gut effects are real and sometimes silent. Thoughtful use–matching dose and duration to clinical need–helps reduce avoidable intestinal stress, especially in patients with prior gastrointestinal disease or persistent digestive symptoms.

NSAIDs – A Balanced Approach to Gut Protection

In clinical decision-making, NSAIDs are best viewed as situational medicines rather than everyday solutions. When pain control is needed, physicians weigh the expected benefit against gastrointestinal vulnerability and consider whether non-NSAID strategies could achieve the same goal.

If longer courses are unavoidable, clinicians may prefer agents with a more selective mechanism and the lowest effective dose, recognizing that individual tolerance varies and that no option is entirely risk-free for the intestine.

The way NSAIDs are taken also matters. Co-administration with food and avoidance of unnecessary combinations–such as overlapping anti-inflammatory products–can moderate local irritation and reduce cumulative exposure.

Attention to the intestinal barrier becomes part of overall care. Rather than relying on single supplements, the emphasis is on supportive dietary patterns and adequate nutrition, which provide the substrates required for mucosal repair and microbial stability.

After periods of NSAID use, clinicians often focus on gradual ecological recovery. Diets containing a variety of plant fibers and minimally processed foods help create conditions in which short-chain-fatty-acid production and microbial diversity can re-establish without aggressive interventions.

Microbiota Effects

• NSAID exposure has been associated with shifts in SCFA-producing bacteria, which may influence epithelial repair and barrier resilience, although changes vary between individuals and drug types [111].
• NSAIDs can increase intestinal permeability, and in susceptible patients this may promote greater immune exposure to bacterial products; progression to clinically relevant systemic inflammation is context-dependent rather than universal [531].
• Alterations in microbial profiles have been reported during NSAID therapy, including relative expansion of Pseudomonadota (formerly Proteobacteria), but these patterns are heterogeneous and strongly influenced by co-medications such as proton-pump inhibitors.
• Mucosal immune responses can be modified by repeated NSAID use, potentially lowering resistance to local infections or bacterial overgrowth in vulnerable individuals.
• The relationship between NSAIDs and inflammatory bowel disease is complex; some studies suggest higher risk of flares with non-selective agents, yet causality remains uncertain and depends on patient-specific factors and exposure characteristics.

Patient Guidance

• Use NSAIDs only when there is a clear need. Avoid taking them for minor or routine discomfort if other options can help.
• Take the lowest dose for the shortest time. Longer courses increase gut risk without adding extra benefit for many conditions.
• Prefer taking NSAIDs with food and water. This can reduce direct irritation of the gut lining.
• Avoid mixing several painkillers at the same time unless your doctor specifically advises it.
• Be cautious if you have prior gut disease, anemia, or regular stomach symptoms. Discuss alternatives early.
• Watch for warning signs: black stools, persistent abdominal pain, new diarrhea, or unexplained fatigue require medical review.
• After an NSAID period, focus on simple gut-friendly meals with vegetables, fruits, legumes, and whole grains as tolerated.
• Limit alcohol during NSAID use to reduce combined irritation of the gut.
• If long-term pain treatment is needed, ask about non-NSAID strategies such as physiotherapy, topical treatments, or other medication classes.
• Remember: protecting your gut is part of treating your pain.

Key evidence: the bidirectional NSAID–microbiome relationship

The 2020 review by Maseda and Ricciotti in Frontiers in Pharmacology provides the most detailed synthesis of the bidirectional NSAID–microbiome interaction. On one side, the gut microbiota can chemically modify NSAIDs themselves and indirectly influence their absorption and metabolism – and through this, their therapeutic efficacy and their toxicity. On the other, NSAIDs directly alter the composition and function of the gut flora and can induce dysbiosis by modifying host physiology. [748]

Of practical importance, a proton pump inhibitor given routinely for gastric protection does not protect the small intestine – on the contrary. In the 2011 Gastroenterology paper by Wallace and colleagues, omeprazole reduced jejunal Actinobacteria and Bifidobacterium populations by approximately 80% in an animal model, thereby aggravating NSAID-induced small intestinal injury; restoring the depleted Bifidobacterium-enriched commensals prevented ulceration and bleeding in the experiment. [749] This result, however, derives from an animal model. For chronic NSAID users there is currently no validated human protocol prescribing a combination of a proton pump inhibitor and a Bifidobacterium-containing probiotic for microbiota protection; at the level of the small intestine the available data make the proton pump inhibitor a risk factor rather than a protective one, so co-administration is in every case a decision for the treating physician, based on the individual indication.

References

[111] Koh A, De Vadder F, Kovatcheva-Datchary P, Bäckhed F. From Dietary Fiber to Host Physiology: Short-Chain Fatty Acids as Key Bacterial Metabolites. Cell. 2016. Link

Mechanistic review of short-chain fatty acids (SCFAs), produced by bacterial fermentation of dietary fibre. Fermentable fibre is the primary energy source for the colonic microbiota; the main fermentation products are **acetate, propionate and butyrate**. **Butyrate is the principal energy substrate of colonocytes**; SCFAs also influence barrier integrity, immune function and, once in the circulation, host metabolism, partly via G-protein-coupled receptors (GPR41/43) and histone deacetylase inhibition. This entry is the source for the textbook-level claims of III.2 (S-0302-01, -02). Important: a **review**, not original experimental data.

[531] Cani PD, Amar J, Iglesias MA et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007. Link

Bacterial lipopolysaccharide (LPS) is identified as a triggering factor for insulin resistance, obesity and diabetes. Plasma LPS fluctuates with feeding/fasting and a 4-week high-fat diet chronically increased it 2-3-fold ("metabolic endotoxemia") while increasing the proportion of LPS-containing gut microbiota. Inducing comparable metabolic endotoxemia in mice via continuous subcutaneous LPS infusion for 4 weeks reproduced the high-fat-diet phenotype: increased fasting glycaemia and insulinaemia, weight gain, adipose F4/80+ inflammation, and hepatic triglyceride accumulation.

[619] Syer SD, Blackler RW, Wallace JL. NSAID enteropathy and bacteria: a complicated relationship. . 2015. Link

Syer, Blackler and Wallace (J Gastroenterol, 2015; 50:387-393) review the role of the gut microbiota in the pathogenesis of NSAID-induced small intestinal injury (NSAID enteropathy). They emphasize that germ-free animals are resistant to NSAID-induced small-bowel damage, whereas bacterial colonization (particularly gram-negative organisms) renders them susceptible, demonstrating that the microbiota is required for enteropathy. The mechanism involves enterohepatic circulation of NSAIDs, bacterial deconjugation (beta-glucuronidase) and endotoxin release.

[620] Wallace JL. NSAID gastropathy and enteropathy: distinct pathogenesis likely necessitates distinct prevention strategies. . 2012. Link

Wallace's 2012 British Journal of Pharmacology review distinguishes the divergent pathogenesis of NSAID-induced gastric (gastropathy) versus small-intestinal injury (enteropathy). Enteropathy is driven not primarily by prostaglandin-synthesis inhibition but by enterohepatic circulation of NSAIDs: carboxylic-acid NSAIDs are conjugated in the liver to acyl glucuronides, excreted in bile to the small intestine, where bacterial beta-glucuronidase deconjugates them back to the active aglycone, which damages the mucosa at locally high concentration and is reabsorbed. In germ-free or antibiotic-treated animals this cycle — and the injury — does not occur, demonstrating the causal role of the microbiota. The author stresses that gastropathy and enteropathy require distinct prevention strategies.

[748] Maseda D, Ricciotti E. NSAID-Gut Microbiota Interactions. Frontiers in Pharmacology. 2020. Link

Review of the bidirectional interaction between non-steroidal anti-inflammatory drugs (NSAIDs) and the gut microbiota. NSAIDs relieve pain, inflammation and fever by inhibiting the cyclooxygenase isozymes (COX-1 and COX-2), but despite their clinical efficacy they can cause gastrointestinal and cardiovascular complications. The gut microbiota can directly chemically modify NSAIDs or indirectly influence their absorption and metabolism, thereby shaping NSAID disposition, therapeutic efficacy and toxicity. Conversely, NSAIDs can directly alter the composition and function of the gut microbiota, or indirectly alter host physiological properties in ways that precipitate dysbiosis. Keywords: NSAIDs, microbiota, dysbiosis, enteropathy, prostanoid, cyclooxygenase.

[749] Wallace JL, Syer S, Denou E, de Palma G, Vong L, McKnight W, Jury J, Bolla M, Bercik P, Collins SM, Verdu E, Ongini E. Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis. Gastroenterology. 2011. Link

Animal study of how proton pump inhibitor treatment affects NSAID-induced small intestinal injury. Omeprazole treatment produced marked shifts in enteric bacteria, including an approximately 80% reduction in jejunal Actinobacteria and Bifidobacteria. Restoring small intestinal Actinobacteria numbers by administering selected Bifidobacteria-enriched commensal bacteria during combined omeprazole and naproxen treatment prevented intestinal ulceration and bleeding. The authors conclude that PPIs exacerbate NSAID-induced intestinal damage at least in part because of significant shifts in enteric microbial populations. Important limitation: the finding derives from an animal model and has not been validated as a human protocol.